Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ian L. Fox"'
Autor:
Jason S. Lewis, Nagavarakishore Pillarsetty, Thomas R. Dilling, Maria Davydova, Ian L. Fox, Adam O. Michel, Mike Cornejo, Veronica L. Nagle, Kyeara N. Mack, Kelly E. Henry
Supplementary Materials and Methods. Supplementary Figure 1. Fibroblast isolation from orthotopic PDAC tumor microenvironment. Supplementary Figure 2. Controls for immunofluorescence experiments to confirm no cross-reactivity or non-specific binding,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a066b185f31d6aaf3af1dfcc88dc5d34
https://doi.org/10.1158/1535-7163.22520551.v1
https://doi.org/10.1158/1535-7163.22520551.v1
Autor:
Jason S. Lewis, Nagavarakishore Pillarsetty, Thomas R. Dilling, Maria Davydova, Ian L. Fox, Adam O. Michel, Mike Cornejo, Veronica L. Nagle, Kyeara N. Mack, Kelly E. Henry
Patients with pancreatic ductal adenocarcinoma (PDAC) do not benefit from immune checkpoint blockade (ICB) along the PD-1/PD-L1 axis. Variable PD-L1 expression in PDAC indicates a potential access issue of PD-L1–targeted therapy. To monitor target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8891e60b9376a9e53f82e6eda47b7a41
https://doi.org/10.1158/1535-7163.c.6542677.v1
https://doi.org/10.1158/1535-7163.c.6542677.v1
Autor:
Jason S. Lewis, Michael J. Evans, Ian L. Fox, Jonathan D. Caen, Thomas R. Dilling, Megan M. Dacek, Kelly E. Henry
Supplementary Data file with additional experimental and figures. SUPPLEMENTAL FIGURE 1: Radiolabeling of [89Zr]Zr-transferrin as shown by instant thin layer chromatography. Radiochemical yield ranged from 60-70% and all radiochemical purity was >99%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::535ab87705c4fa629a931cb7739139f9
https://doi.org/10.1158/1078-0432.22476051.v1
https://doi.org/10.1158/1078-0432.22476051.v1
Autor:
Mike Cornejo, Jason S. Lewis, Ian L. Fox, Thomas R. Dilling, Adam O. Michel, Kelly E. Henry, Nagavarakishore Pillarsetty, Maria Davydova, Veronica L. Nagle, Kyeara N. Mack
Publikováno v:
Mol Cancer Ther
Patients with pancreatic ductal adenocarcinoma (PDAC) do not benefit from immune checkpoint blockade (ICB) along the PD-1/PD-L1 axis. Variable PD-L1 expression in PDAC indicates a potential access issue of PD-L1–targeted therapy. To monitor target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f8765325d41917d3d55ab80fbebebd5
https://pubmed.ncbi.nlm.nih.gov/34349003
https://pubmed.ncbi.nlm.nih.gov/34349003
Autor:
Megan M. Dacek, Kelly E. Henry, Thomas R. Dilling, Jonathan D. Caen, Michael J. Evans, Ian L. Fox, Jason S. Lewis
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(1)
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, with a 5-year survival rate of less than 10%. Physicians often rely on biopsy or CT to guide treatment decisions, but these techniques fail to reliably measure the ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e6172ec57c6ae99ac740a21fbe188e2
https://pubmed.ncbi.nlm.nih.gov/30228208
https://pubmed.ncbi.nlm.nih.gov/30228208